A Global Leader


Manufacturer of instruments and reagents for in-vitro diagnostics


Revenue growth


Instruments in installed base


Countries products sold into

A global leader in the diagnostics of serum protein with a superior technology in electrophoresis. Sebia is a research-driven company covering several pathologies including multiple myeloma, diabetes (HbA1c) and haemoglobin deficiencies. Montagu originally acquired the business in 2006 and invested for a second time in 2014.

A Montagu business

  • A global leader in electrophoresis with cutting-edge technology
  • Highly recurring revenues
  • Strong market dynamics increasing demand and potential to grow emerging market sales

Supporting international expansion

Between 2014 and 2018, we supported Sebia:

  • In the successful launch and development of its new generation instrument the Capillarys 3
  • Accelerate penetration of the diabetes market
  • Complete the strategic acquisition of Italian competitor Interlab

Sebia was sold to a consortium of long term investors: Caisse de dépôt et placement du Québec (CDPQ), Téthys and CVC’s long term fund.